Cooper Co stock kpis
Want to see COO full AI Analyst Report?
Revenue by Segment
Shows how different parts of the business contribute to overall sales, highlighting strengths and potential areas for growth within the company's diverse operations.
CooperVision is the steady-growth engine—consistent organic lens demand and new product momentum (MiSight, daily silicone hydrogel) underpin resilience even as Asia softness and near-term margin pressure from FX, tariffs and inventory optimization bite. CooperSurgical is the faster-growth lever—fertility, genomics and capital equipment have materially lifted contribution since 2022, and management’s strategic review (broad external interest) could unlock value or introduce execution risk. Monitor how litigation payouts and any transaction proceeds affect buybacks, FCF allocation and near-term margin recovery.
COO Revenue by Segment
| Date | CooperVision | CooperSurgical |
|---|---|---|
| Jul 31, 2026 | $717.00M | $349.20M |
| Apr 30, 2026 | $723.50M | $358.00M |
| Jan 31, 2026 | $695.10M | $329.00M |
| Oct 31, 2025 | $709.60M | $355.60M |
| Jul 31, 2025 | $718.40M | $341.90M |
| Apr 30, 2025 | $669.60M | $332.70M |
| Jan 31, 2025 | $646.10M | $318.60M |
| Oct 31, 2024 | $676.40M | $342.00M |
| Jul 31, 2024 | $675.60M | $327.20M |
| Apr 30, 2024 | $635.90M | $306.70M |
| Jan 31, 2024 | $621.50M | $310.10M |
| Oct 31, 2023 | $622.90M | $304.20M |
| Jul 31, 2023 | $630.20M | $300.00M |
| Apr 30, 2023 | $589.30M | $288.10M |
| Jan 31, 2023 | $581.30M | $277.20M |
| Oct 31, 2022 | $561.70M | $286.30M |
| Jul 31, 2022 | $566.30M | $277.10M |
| Apr 30, 2022 | $553.80M | $276.00M |
| Jan 31, 2022 | $561.50M | $225.70M |
| Oct 31, 2021 | $564.90M | $194.20M |
| Jul 31, 2021 | $557.50M | $205.90M |
| Apr 30, 2021 | $522.60M | $196.90M |
| Jan 31, 2021 | $507.00M | $173.50M |
| Oct 31, 2020 | $506.30M | $175.30M |
| Jul 31, 2020 | $449.30M | $128.90M |
| Apr 30, 2020 | $402.20M | $122.70M |
| Jan 31, 2020 | $485.20M | $161.00M |

